Program
Dronedarone
Also written as “Dabigatran etexilate plus dronedarone”, “Dronedarone (SR33589)” and “Dronedarone Hydrochloride Tablets”.
Its studies are mostly in Atrial Fibrillation · Heart Failure, led by 4 companies.
Drug pageDronedarone: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 140 open or running | phase 4since Dec 2, 2009 | Sep 13, 2005 | none ahead |
| Lunan Pharmaceutical Group | 20 open or running | no phasesince Jan 27, 2026 | Jan 27, 2026 | none ahead |
| Boehringer Ingelheimits history only | 10 open or running | phase 1since Feb 28, 2011 | Feb 28, 2011 | none ahead |
| Gilead Sciencesits history only | 10 open or running | phase 2since Jan 18, 2012 | Jan 18, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Lunan Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 27, 2026First studies: 2 no phase studies in Atrial FibrillationFirst studyNCT07396519, NCT07396506
TargetBeta
“Voltage-gated L-type calcium channel blocker; Sodium channel alpha subunit blocker; Inward rectifier potassium channel 2 blocker; Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker”ChEMBL 37, by rule
Studies
All 2 Lunan Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07396519Atrial Fibrillation · China | – | Completed | Dec 7, 2022 | 48 |
| NCT07396506Atrial Fibrillation · China | – | Completed | Jul 10, 2023 | 51 |
How it is read
Names in the registry
- “Dronedarone”, 7 entries
- “Dabigatran etexilate plus dronedarone”, 4 entries
- “Dronedarone (SR33589)”, 4 entries
- “Dronedarone Hydrochloride Tablets”, 2 entries
- “dronedarone (SR33589)”, 2 entries
Conditions, from the studies’ own filings
- Atrial Fibrillation, 16 studies
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.